Example: Heart Attack

Search clinical trials for: Modulation of FiO2

Total 10000 results

NCT00225849

Unknown

Japanese Primary Prevention Project With Aspirin

Hypertension | Diabetes Mellitus | Hyperlipidemia
NCT06725121

Recruiting

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant (MacroTrans)

Hepatocellular Carcinoma (HCC) | Liver Transplant Surgery | Macrovascular Invasion | Downstaging
NCT06518317

Recruiting

Short Versus Long Antiplatelet Therapy After TAVI (SOLOTAVI)

Transcatheter Aortic Valve Replacement
NCT06503263

Not yet recruiting

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

Diffuse Large B-cell Lymphoma
NCT06192680

Not yet recruiting

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Colorectal Cancer
NCT06067217

Recruiting

Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users

Abnormal Uterine Bleeding | Tranexamic Acid | Estrogen | Depot Medroxyprogesterone Acetate
NCT06003998

Recruiting

Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab (INTERACT-II)

Colorectal Cancer | Peritoneal Metastases
NCT05833126

Recruiting

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Recurrent Liver Cancer After Liver Transplantation
NCT05798819

Not yet recruiting

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Persistent, Recurrent, or Metastatic Cervical Cancer
NCT05477797

Recruiting

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Overall Survival | Progression Free Survival | Maintenance
NCT05002127

Active, not recruiting

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
NCT06982196

Enrolling by invitation

Sulodexide in Controlling the Recurrence of Psoriasis

Psoriasis (PsO) | Randomised Controlled Trial
NCT00513786

Completed

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Endometrial Cancer
NCT06755515

Enrolling by invitation

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Cervical Cancer
NCT04325698

Terminated

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

Advanced Non-squamous NSCLC
NCT02743221

Completed

A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1)

Metastatic Colorectal Cancer
NCT00998166

Terminated

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

Non-Small Cell Lung Cancer
NCT00020046

Completed

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer
NCT03766425

Completed

Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.

Eye Diseases | Glaucoma Surgery | Optic Nerve Damage
NCT05340205

Completed

Blood Loss During Cesarean Delivery in Placenta Previa Patients

Placenta Previa
NCT01180959

Completed

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Liver Cancer
NCT04778917

Completed

Observation and Treatment of Pulmonary Microthrombosis in Childhood Pneumonia With Elevated D-dimer

Pneumonia
NCT01847573

Terminated

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy
NCT03367143

Unknown

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Diffuse Large B-Cell Lymphoma Refractory
NCT00974233

Completed

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
NCT03912402

Unknown

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

Cervical Cancer | Cervical Cancer Recurrent | Cervical Cancer Metastatic
NCT01303965

Terminated

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Multiple Myeloma
NCT03751163

Completed

Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma

Melasma
NCT03585179

Unknown

Oral and Topical Tranexamic Acid for the Treatment of Melasma (TRANEXAMICO)

Melanosis | Melasma | Chloasma
NCT02355028

Completed

LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

Exudative Age-Related Macular Degeneration
NCT00006358

Completed

Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor

Brain and Central Nervous System Tumors
NCT02966002

Terminated

Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients

Fontan Procedure
NCT00365144

Completed

Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

Pancreatic Cancer
NCT03191981

Withdrawn

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma (MUKfourteen)

Myeloma Multiple
NCT03038607

Completed

Aspirin in Asymmetrically Intrauterine Growth

Intrauterine Growth Restriction Asymmetrical
NCT00798603

Completed

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer
NCT01894555

Completed

Pharmacogenomics of Antiplatelet Response - II (PARes-II) (PARes-II)

Atherothrombosis
NCT01201265

Completed

A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer

Breast Cancer
NCT00942617

Withdrawn

Measurement of Platelet Dense Granule Release in Healthy Volunteers

Platelet Aggregation
NCT00276575

Completed

Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
NCT02283489

Unknown

Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors

Head and Neck Neoplasms
NCT00098865

Completed

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

Neuroblastoma | Central Nervous System Tumor, Pediatric
NCT00611728

Completed

Ph I SU011248 + Irinotecan in Treatment of Pts w MG

Glioblastoma
NCT00626561

Terminated

Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix

Cervical Cancer | Uterine Cancer
NCT02084342

Unknown

Study of DDAVP Combined With TXA on the Blood Loss and Transfusion Need During and After Scoliosis Correction Surgery

Idiopathic Scoliosis
NCT00033709

Unknown

Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma

Sarcoma
NCT00096018

Completed

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Leukemia
NCT00670982

Completed

Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer

Breast Cancer
NCT00427310

Completed

Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery

Colorectal Cancer
NCT00849550

Completed

Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors. (COBRA)

Cancer | Unspecified Adult Solid Tumor, Protocol Specific

Search clinical trials for: Modulation of FiO2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations